- 2013. Therapeutic Goods Administration. Australian Code of Good Manufacturing Practice for Human Blood and Blood Components, Human Tissue and Human Cellular Therapy Products. Australia.
- 2012. Federal Register. Food and Drug Administration. Amendments to Sterility Test Requirements for Biological Products Final Rule. 21 CFR Parts 600, 610, and 680 [Docket No. FDA–2011–N–0080]. 77(86): 26162-26175.
- 2012. European Commission. EU guidelines to good manufacturing practice, Annex 2. Manufacture of Biological active substances and Medicinal Products for Human Use. EudraLex, European Union: Brusselles, Belgium.
- 2010. European Commission. EU guidelines to good manufacturing practice, Annex 14. Manufacture of Medicinal Products Derived from Human Blood or Plasma. EudraLex, European Union: Brusselles, Belgium.
- 2008. European Commission. EU guidelines to good manufacturing practice, Annex 1. Manufacture of sterile medicinal products (corrected version). EudraLex, European Union: Brusselles, Belgium.
- 2004. Food and Drug Administration. Guidance for Industry: Sterile drug products produced by aseptic processing -Current good manufacturing practice. U.S. Department of Health and Human Services, Rockville, Maryland.
- 2004. Food and Drug Administration. Final report for pharmaceutical cGMPs for the 21st Century – A risk-based approach. U.S. Department of Health and Human Services, Rockville, Maryland.
- 2000. International Conference on Harmonization. Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients – Q7. Geneva, Switzerland.
Cell Therapy Microbiology Consulting, LLC